Tagrisso demonstrated strong overall survival benefit in Phase III ADAURA trial for adjuvant treatment of patients with early-stage EGFR-mutated lung cancer – AstraZeneca

  1. Tagrisso Demonstrated a Strong Overall Survival Advantage in the Phase III ADAURA Trial for the Adjuvant Treatment of Patients With Early-Stage EGFR Mutated Lung CancerAstra Zeneca
  2. AstraZeneca touts 2 lung cancer wins as Keytruda showdown loomsFiercePharma
  3. Osimertinib adjuvant induces improved OS in early-stage EGFR-mutated NSCLCOncLive
  4. AstraZeneca says cancer drug Imfinzi improves chances of survival in late-stage trialReuters.com
  5. News Highlights: AstraZeneca claims cancer drug Imfinzi improves chances of survivalMoney control
  6. See full coverage on Google News

Leave a Comment

Your email address will not be published. Required fields are marked *